Hypoxia-inducible factor-1α (HIF-1α) has become a significant therapeutic target for breast cancer and other cancers by regulating the expression of downstream genes such as erythropoietin, thereby improving cell survival in hypoxic conditions. The gene discussed is EPO; the disease is cancer.